BIO-key International Finalizes 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance
summarizeSummary
BIO-key International, Inc. has finalized a 1-for-10 reverse stock split, effective April 29, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
check_boxKey Events
-
Reverse Stock Split Finalized
The Board of Directors has set the reverse stock split ratio at 1-for-10, following stockholder approval on April 20, 2026.
-
Effective Date and Trading
The Certificate of Amendment becomes effective at 5:00 p.m. Eastern Time on April 29, 2026. Common Stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on April 30, 2026.
-
Share Reduction
The total outstanding shares of Common Stock will be reduced from approximately 10,852,118 to approximately 1,085,212 after the split.
-
Purpose for Nasdaq Compliance
The reverse stock split is intended to position the company for minimum bid price compliance with Nasdaq listing requirements.
auto_awesomeAnalysis
This filing confirms the implementation details of the reverse stock split previously approved by stockholders on April 20, 2026. The Board's decision to set the ratio at 1-for-10 is a critical step for BIO-key International to address its non-compliance with Nasdaq's minimum bid price requirement. While necessary for continued listing, reverse splits are generally viewed negatively by the market as they often signal underlying challenges with a company's stock performance, especially when trading near 52-week lows. Investors should monitor the stock's performance post-split and the company's ability to maintain compliance and execute on its growth goals.
At the time of this filing, BKYI was trading at $0.47 on NASDAQ in the Technology sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.46 to $1.97. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.